Liu Fu-Chao, Day Yuan-Ji, Liao Chang-Hui, Liou Jiin-Tarng, Mao Chih-Chieh, Yu Huang-Ping
Department of Anesthesiology Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan Tao-Yuan, Taiwan 333.
Anesth Analg. 2009 Jun;108(6):1855-61. doi: 10.1213/ane.0b013e3181a1a194.
Hemeoxygenase-1 induction in response to adverse circulatory conditions is protective. Our recent study has shown that administration of sirtinol attenuates hepatic injury in male Sprague-Dawley rats after trauma-hemorrhage; however, the mechanism by which sirtinol produces the salutary effects remains unknown. We hypothesized that sirtinol administration in male Sprague-Dawley rats after trauma-hemorrhage decreases cytokine production and protects against lung injury through a hemeoxygenase-1 related pathway.
Male Sprague-Dawley rats (n = 8 per group) underwent trauma-hemorrhage (mean arterial blood pressure 40 mm Hg for 90 min, then resuscitation). A single dose of sirtinol (1 mg/kg of body weight) with or without a hemeoxygenase enzyme inhibitor (chromium-mesoporphyrin) or vehicle was administered IV during resuscitation. Twenty-four hours thereafter, myeloperoxidase activity (a marker of neutrophil sequestration) and tumor necrosis factor alpha, interleukin-6, and interleukin-10 levels in the lung, protein concentrations in bronchoalveolar lavage fluid and tissue histology were measured. Lung hemeoxygenase-1 protein level was also determined.
In the sirtinol-treated rats subjected to trauma-hemorrhage, there were significant improvements in lung myeloperoxidase activity (4.68 +/- 0.31 vs 9.36 +/- 1.03 U/mg protein, P < 0.05), tumor necrosis factor alpha levels (710.7 +/- 28 vs 1288 +/- 40.69 pg/mg protein, P < 0.05), interleukin-6 levels (343.6 +/- 18.41 vs 592.7 +/- 22.3 pg/mg protein, P < 0.05), and protein concentrations (303.8 +/- 24.54 vs 569.6 +/- 34.82 microg/mL, P < 0.05) and lesser damage in histology. There was no statistically significant difference in interleukin-10 levels in the lung between sirtinol-treated trauma-hemorrhaged rats and vehicle-treated trauma-hemorrhaged rats (842.5 +/- 54.18 vs 756.2 +/- 41.34 pg/mg protein, respectively). Lung hemeoxygenase-1 protein levels were increased in rats receiving sirtinol treatment as compared with vehicle-treated trauma-hemorrhaged rats (5.18 +/- 0.25 vs 2.70 +/- 0.16, P < 0.05). Administration of the hemeoxygenase inhibitor chromium-mesoporphyrin prevented the sirtinol-induced attenuation of shock-induced lung damage.
The salutary effects of sirtinol administration on attenuation of lung inflammation after trauma-hemorrhage are mediated via upregulation of hemeoxygenase-1 expression.
血红素加氧酶-1在应对不良循环状况时的诱导具有保护作用。我们最近的研究表明,给予西地尼布可减轻雄性Sprague-Dawley大鼠创伤性出血后的肝损伤;然而,西地尼布产生有益作用的机制尚不清楚。我们假设,雄性Sprague-Dawley大鼠创伤性出血后给予西地尼布可减少细胞因子产生,并通过血红素加氧酶-1相关途径预防肺损伤。
雄性Sprague-Dawley大鼠(每组8只)经历创伤性出血(平均动脉血压40 mmHg,持续90分钟,然后进行复苏)。在复苏期间静脉注射单剂量西地尼布(1 mg/kg体重),同时给予或不给予血红素加氧酶抑制剂(铬-中卟啉)或赋形剂。此后24小时,测量肺中的髓过氧化物酶活性(中性粒细胞隔离的标志物)、肿瘤坏死因子α、白细胞介素-6和白细胞介素-10水平、支气管肺泡灌洗液中的蛋白质浓度以及组织组织学。还测定了肺血红素加氧酶-1蛋白水平。
在接受西地尼布治疗的创伤性出血大鼠中,肺髓过氧化物酶活性(4.68±0.31 vs 9.36±1.03 U/mg蛋白,P<0.05)、肿瘤坏死因子α水平(710.7±28 vs 1288±40.69 pg/mg蛋白,P<0.05)、白细胞介素-6水平(343.6±18.41 vs 592.7±22.3 pg/mg蛋白,P<0.05)和蛋白质浓度(303.8±24.54 vs 569.6±34.82 μg/mL,P<0.05)有显著改善,组织学损伤较轻。接受西地尼布治疗的创伤性出血大鼠与接受赋形剂治疗的创伤性出血大鼠肺中白细胞介素-10水平无统计学显著差异(分别为842.5±54.18 vs 756.2±41.34 pg/mg蛋白)。与接受赋形剂治疗的创伤性出血大鼠相比,接受西地尼布治疗的大鼠肺血红素加氧酶-1蛋白水平升高(5.18±0.25 vs 2.70±0.16,P<0.05)。给予血红素加氧酶抑制剂铬-中卟啉可预防西地尼布诱导的休克诱导性肺损伤减轻。
西地尼布给药对创伤性出血后减轻肺部炎症的有益作用是通过上调血红素加氧酶-1表达介导的。